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Abstract: Obesity is a major public health problem affecting adults and children in both 
developed and developing countries. This condition often leads to metabolic syndrome, which 
increases the risk of cardiovascular disease. A large number of studies have been carried out 
to understand the pathogenesis of cardiovascular dysfunction in obese patients. Endothelial 
  dysfunction plays a key role in the progression of atherosclerosis and the development of 
coronary artery disease, hypertension and congestive heart failure. Noninvasive methods in 
the field of cardiovascular imaging, such as measuring intima-media thickness, flow-mediated 
dilatation, tissue Doppler, and strain, and strain rate, constitute new tools for the early detection 
of cardiac and vascular dysfunction. These techniques will certainly enable a better evaluation 
of initial cardiovascular injury and allow the correct, timely management of obese patients. 
The present review summarizes the main aspects of cardiovascular dysfunction in obesity and 
discusses the application of recent noninvasive imaging methods for the early detection of 
cardiovascular alterations.
Keywords: cardiovascular risk, endothelium dysfunction, obesity, strain and strain rate, tissue 
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Introduction
The prevalence of overweight and obesity is increasing at a very high rate, affecting an 
estimated 300 million individuals worldwide. A number of studies carried out in devel-
oping countries report an approximate 20% prevalence of obesity.1–3 The prevalence 
is even higher in developed countries. In 2007–2008, obesity in the United States was 
reported to affect 32.21% of male adults and 35.5% of female adults.4,5 Considering 
the standard definition for overweight and obesity in the pediatric population (2 to 
19 years of age), 11.9% were at or above the 97th percentile of the body mass index 
(BMI), 16.9% were at or above the 95th percentile and 31.7% were at or above the 
85th percentile.6–8 Childhood obesity increases the risk of obesity in adulthood tenfold 
and pediatric patients that persistently remain at the 99th BMI percentile are at very 
high risk for severe adult obesity.9,10
Obesity is commonly associated with a combination of comorbidities, which 
collectively comprise metabolic syndrome. In 1998, the World Health Organization 
published a definition for metabolic syndrome that includes insulin resistance, raised 
plasma triglycerides, low high-density lipoprotein, central obesity or a BMI greater 
than 30 kg/m2 for adults and above the 95th percentile for children and adolescents, 
microalbuminuria (.20 µg/min) or elevated albumin-to-creatinine ratio ($30 mg/g) 
and hypertension.11,12 Recently, a number of other clinical and laboratorial features Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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have been associated with metabolic syndrome, such as 
  nonalcoholic fatty liver disease, polycystic ovarian   syndrome, 
atherosclerosis, proinflammatory state and oxidative stress. 
Moreover, body measurements, such as the waist-to-hip ratio 
and waist circumference, seem to predict the risk of mortality 
better than the BMI.12,13
Cardiovascular complications associated with   obesity 
contribute to high rates of morbidity and mortality. 
  Hypertension is three to five times more common in obese 
subjects in comparison to individuals within the ideal 
weight range.14 All components of metabolic syndrome are 
  independent predictors of cardiovascular events, such as 
stroke, cardiomyopathy, coronary artery disease, myocar-
dial infarction, congestive heart failure and sudden cardiac 
death.15 Central (mesenteric and omental) obesity is highly 
correlated to the risk of cardiovascular disease.16–18 The 
risk of death among obese individuals (BMI . 30 kg/m2) 
is two to three times higher than nonobese individuals and 
the severely obese individuals (BMI . 35 kg/m2) have a 
5-to-20-year decrease in life expectancy in comparison to 
nonobese individuals matched for age and gender.14,16
The present review summarizes the main aspects of 
cardiovascular dysfunction in obesity and discusses the 
application of recent noninvasive imaging methods in this 
context.
Endothelial dysfunction in obesity
Endothelial dysfunction is associated with a large number 
of clinical conditions and laboratorial alterations, includ-
ing diabetes mellitus, hypercholesterolemia, hypertension, 
insulin resistance, advanced age and obesity.19 Adipose tissue 
plays a key role in the development of endothelial dysfunc-
tion in obese patients.20 An increase in fat mass increases 
the size and number of adipocytes. Changes associated with 
adipocyte hypertrophy seem to produce cell dysfunction. 
An excessive amount of lipid stored in adipocytes leads to 
functional abnormalities of the endoplasmic reticulum and 
mitochondria, which, in turn, contribute to intracellular and 
systemic disorders such as the stimulation of a proinflam-
matory state, insulin resistance, and high production of free 
fatty acids (FFAs).21 FFAs accumulate in nonadipose tissue 
and cause an overproduction of metabolic toxins. Both 
effects impair insulin signaling and glucose tolerance.22 
Nonalcoholic fatty liver disease also plays a very important 
role in this process.23
In addition, chronic subclinical inflammation associ-
ated with visceral and central adiposity often occurs in 
patients with metabolic syndrome. The major mediators 
responsible for the balance between proinflammatory and 
  anti-inflammatory pathways are C-reactive protein (CRP), 
leptin, tumor necrosis factor α (TNF-α), interleukin-6 
(IL-6), serum retinol-binding protein 4 (sRBP-4), plasmi-
nogen activator inhibitor 1 (PAI-1), nitric oxide (NO), and 
adiponectin.21,24–27 Fat in the liver also represents a site beyond 
adipose tissue that independently contributes to the synthesis 
of inflammatory mediators such as CRP, IL-6 and PAI-1, 
which are increased in nonalcoholic fatty liver disease.23,28 
The predominance of inflammatory mediators in obese 
patients also contributes to endothelial dysfunction.
CRP is predominantly produced by the liver in response 
to IL-6 and is chronically elevated in metabolic syndrome. 
CRP levels are positively correlated with BMI and visceral 
fat accumulation.29 CRP inhibits the formation of NO by 
endothelial cells. The lack of NO promotes vasoconstric-
tion, leukocyte adherence, platelet activation, oxidation, 
and thrombosis, thereby leading to endothelial dysfunction 
and arterial hypertension.21,24 High levels of CRP are also 
predictive of atherothrombotic events.26
Leptin is secreted by adipose tissue. This secretion is 
directly proportional to adipose tissue mass. Leptin receptors 
are mainly expressed in the hypothalamus and brainstem 
neuronal circuit and control satiety, energy expenditure, 
and neuroendocrine functions. Obese patients have elevated 
levels of endogenous leptin that fail to suppress appetite, thus 
characterizing a leptin-resistant state. High levels of leptin 
have been linked to vasculopathy via obesity associated with 
hypertension.20,25,30 High leptin levels are also associated with 
insulin resistance and correlated with artherosclerosis and 
coronary artery calcifications.31,32
TNF-α is a proinflammatory cytokine whose expression 
is elevated in obese adipose tissue. This cytokine is mainly 
produced from macrophages within the adipose tissue as well 
as adipocytes themselves.21,33 There is a strong relationship 
between TNF-α and the effect of the lipoprotein lipase, which 
is responsible for the breakdown of circulating triglycerides 
and very-low-density cholesterol. In metabolic syndrome, 
there is an increase in macrophage TNF-α expression and 
a decrease in the effect of lipoprotein lipase, thereby caus-
ing hypertriglyceridemia. TNF-α impairs insulin signaling 
by an increase in circulating FFAs, which induces insulin 
resistance. TNF-α also plays a role in stimulating the 
expression of other inflammatory mediators, such as IL-6, 
and reduces the expression of anti-inflammatory mediators, 
such as adiponectin.20,25 Furthermore, TNF-α induces insulin 
resistance through the downregulation of the tyrosine kinase 
activity of insulin receptors and the serine phosphorylation Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of insulin substrate 1, which converts this protein into an 
insulin-receptor inhibitor in adipose tissue.34 TNF-α also acti-
vates transcription nuclear factor kappa beta (NF-κβ), which 
induces inflammatory changes within the vessel wall.35,36 
TNF-α is a proinflammatory cytokine that plays a very 
important role in vascular dysfunction in obese patients.
sRBP-4 is a circulating protein of the lipocalin family 
associated with visceral adiposity and insulin resistance. 
sRBP-4 is secreted by the liver and adipocytes, reaching 
high concentrations in chronic low-state inflammation.35 In 
mouse models, sRB4 induces insulin resistance in the liver 
and skeletal muscle.35 In humans, a number of studies report 
an association between sRB4, insulin resistance, and type 2 
diabetes.21
PAI-1 is a member of the serine protease inhibitor   family 
and is the primary inhibitor of fibrinolysis. It is secreted mainly 
by platelets and vascular endothelium and is also produced by 
adipocyte cells. Plasma PAI-1 is elevated in individuals with 
obesity and plays a key role in promoting thrombus formation 
following the rupture of atherosclerotic plaque.25,37
NO has a large number of antiatherogenesis actions, 
including induction of potent vasodilatation, capacity to 
diminish the adhesion of monocytes and the aggregation of 
platelets to the endothelium, and has an inhibitory effect on the 
proliferation of smooth muscle cells.38 Reduced synthesis of 
NO is also an early inducer of obesity. Insulin resistance and 
the chronic rise in plasma glucose enhance the expression of 
glutamine fructose 6 phosphate transaminase, which in turn 
stimulates the production of glucosamine, thereby favoring 
oxidative stress in endothelial cells.39,40 TNF-α also plays a 
role in this process as it inhibits endothelium-dependent vas-
orelaxation by increasing the generation of reactive oxygen 
species, which activate NF-κβ, a transcription regulator of 
molecular adhesion important to the control of inflammatory 
and oxidative states of vascular endothelial cells.19,41–43
Adiponectin is a protein with 247 amino acids produced 
by adipocytes (adipokine) that exerts potent endothelium-
protective effects.44 Adiponectin levels are significantly lower 
in obese individuals in comparison to nonobese individuals 
and have been negatively correlated with percentage of body 
fat, waist-to-hip ratio and abdominal fat.45 Serum adiponectin 
circulates in three forms: low-, middle-, and high-molecular 
weight, which is the most active form. Adiponectin receptors 
are expressed in muscle, liver, and fat cells.46 Low concen-
trations of adiponectin contribute to a variety of obesity-
related diseases, including diabetes, vascular abnormalities, 
and heart disease, and are inversely associated with CRP 
and TNF-α levels.45,46 The main effects of adiponectin are 
the regulation of glucose metabolism, the improvement of 
sensitivity to insulin, the reduction in atherosclerotic lesions, 
the inhibition of monocyte adhesion to endothelial cells, the 
suppression of macrophage transformation into foam cells, 
and the decrease in the proliferation and migration of smooth 
muscle cells.35 It also increases endothelial NO production, 
thereby enhancing vasodilatation and inhibiting platelet 
aggregation. Adiponectin influences cardiac remodeling 
by suppressing pathological heart growth and is believed 
to have a protective effect on ischemic/reperfusion cardiac 
injury.22,44,45,47–49 Nonalcoholic fatty liver disease has been 
also associated to low serum levels of adiponectin.23
Atherosclerosis and coronary  
artery disease in obesity
Obesity is an independent predictor of coronary artery 
  disease. Among men aged under 50 years, obese individuals 
have twice the risk of coronary disease and obese women of 
a similar age have a 2.4-fold greater risk.50
Obesity results in increased deposition of perivascular 
fat around the heart and its major branches. This increased 
adipose tissue surrounding the blood vessels causes the 
overproduction of proinflammatory and profibrotic cytok-
ines, leading to inflammation and atherosclerosis, with a 
consequent increase in intima-media thickness and decrease 
in arterial distensibility.17 The activation of the rennin–
angiotensin–aldosterone system and of the sympathetic 
nervous system in metabolic syndrome leads to an increase 
in coronary vasoconstriction, which significantly contributes 
to the imbalance between coronary blood flow and myocar-
dial metabolism.15 Experimental studies have demonstrated 
that, even in the early stage of obesity, there is a reduction in 
coronary endothelium-dependent vasorelaxation.51
Acute coronary syndromes are usually triggered by the 
rupture or erosion of atheromatous plaque; when the plaque 
ruptures, endothelial tissue factor is exposed to the blood 
and activates the coagulation cascade, causing thrombus 
formation.29
Arterial hypertension in obesity
The prevalence of hypertension in obese patients in the 
United States is on the rise and individuals with a BMI 
greater than 40 have a sevenfold greater likelihood of being 
hypertensive.52 Obesity in children and adolescents also 
leads to hypertension. Chiolero and colleagues conducted 
a prevalence study on hypertension and found that this 
condition was attributed to overweight or obesity in 37% 
of cases.53 In Switzerland, Maggio and colleagues found an Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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association between obese children and systolic hypertension 
in 47.6% of patients as well as an increase in left ventricular 
mass partially caused by high systemic blood pressure.54 
Obese children have a tenfold greater risk of developing 
hypertension as young adults than nonobese children and a 
continuous relationship between BMI and arterial pressure 
has been reported.7,55 One study reports that 10 kg of excess 
body weight is associated with a 3.0-mmHg higher systolic 
and 2.3-mmHg higher diastolic blood pressure.56 Stabouli 
and colleagues57 reported that obese adolescents have higher 
blood pressure and greater carotid artery intima-media thick-
ness in comparison to nonobese pairs.
The mechanism of hypertension in metabolic syndrome 
is highly complex. The obese-related inflammatory state is 
one of the factors probably responsible for hypertension.58 
The inflammatory state leads to hyperinsulinemia, insulin 
resistance, dyslipidemia, and oxidative stress, along with seri-
ous damage to organ systems. Obese patients have increased 
systemic blood volume. The normal compensatory response to 
an elevated cardiac output, which should be a drop in peripheral 
vascular resistance, is hindered in obese patients with hyper-
tension, exhibiting an inappropriately normal total peripheral 
resistance.59 Studies have shown that increased sympathetic 
activity and hypoactivity of the parasympathetic nervous sys-
tem, even in children, also results in an increased incidence of 
hypertension by augmenting sodium retention and vascular 
smooth muscle hypertrophy, affecting glucose delivery to the 
muscles and postprandial lipid clearance.60–62 The increasing of 
the FFAs, along with increased levels of circulating glucose, 
promotes insulin secretion by the pancreas, resulting in hyper-
insulinemia. These events, in turn, can cause increased sodium 
reabsorption and sympathetic nervous system activity, with 
subsequent development or worsening of hypertension.18
The activation of the rennin–angiotensin–aldosterone 
system also significantly contributes to hypertension in obese 
patients.35,60 Adipose tissue is able to synthesize the compo-
nents of the rennin–angiotensin–aldosterone system.35,60 In this 
regard, the formation of angiotensin II in the adipose tissue 
enhances the production of proinflammatory and profibrotic 
cytokines35,50 and stimulates per se vasoconstriction, smooth 
muscle vascular cell proliferation, and endothelial dysfunc-
tion.58 Beside angiotensin II, the elevation of plasma levels of 
aldosterone might promote myocardial tissue growth.60
Left ventricular involvement  
in obesity
Cardiac involvement in obesity has been frequently reported 
in the literature, and the most frequently found abnormalities 
are: increased left ventricular diameters and mass, eccentric 
hypertrophy, diastolic dysfunction and, occasionally, systolic 
dysfunction and heart failure.63–65 Indeed, obesity has been 
linked to a spectrum of minor cardiovascular abnormalities, 
ranging from a hyperdynamic circulation to subclinical 
structural changes.
Congestive heart failure in obesity
Excess weight has been linked to heart failure and   mortality. 
For each increment of one above 30 on the BMI, the risk 
of developing heart failure increases 5% in men and 7% 
in women.50 Obesity has been associated with systolic 
and diastolic heart dysfunction. In a cross-sectional study, 
Ammar and colleagues found a strong correlation between 
left ventricular systolic and diastolic dysfunction and central 
obesity, as measured by the waist-to-hip ratio.66
Studies have documented a better chance of survival from 
cardiac events in patients with decreased left ventricular 
ejection fraction and a higher BMI in comparison to those 
with a lower BMI, which is known as the “obesity paradox”. 
The pathophysiology of the obesity paradox is unknown and 
some authors state that this paradox could be explained by 
an additional disease in patients with low BMI, such as lung 
disease.67 Kapoor and Heidenreich have recently reported 
that the mortality rate in cardiac events is increased in obese 
patients with a BMI of 45 or more in comparison to lean 
peers.68 Moreover, among a cohort of 1,790 patients, Fran-
kenstein and colleagues found that the obesity paradox in 
patients with stable heart failure did not persist after matching 
for clinical characteristics and disease severity.69
There are studies confirming the relationship between 
left atrial size and the development of adverse cardiovascular 
outcomes and those describing a strong correlation between 
BMI and atrial fibrillation, which deteriorates the cardiac 
failure.70,71
The role of noninvasive image 
methods in obesity
Metabolic syndrome and its association with vascular and 
cardiac dysfunction is currently the greatest cause of mortal-
ity and this situation is expected to continue in the future.72 
Noninvasive techniques for evaluating vascular dysfunc-
tion such as flow-mediated dilatation, pulse wave velocity, 
carotid intima-media thickness, and transient elastography to 
evaluate fatty liver disease73 are very good surrogate vascular 
markers. For the early assessment of cardiac dysfunction, 
tissue Doppler, strain, and strain rate have proven useful in 
patients with obesity and other morbidities.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Endothelial dysfunction with a reduction in the bioavail-
ability of endothelium-derived nitric oxide is an early event 
in atherosclerotic change. Flow-mediated inflammation is 
a good way to assess subclinical vascular disease and is 
significantly correlated with invasive tests. Its use with a 
combination of other exams, such as carotid intima-media 
thickness and pulse wave velocity, is of very strong clinical 
importance to the determination of clinical or subclinical 
atherosclerosis.74–76 However, Biasucci and colleagues have 
found that vascular function was paradoxically better among 
severely obese than in nonseverely obese patients and sug-
gested that this group of patients might be partially protected 
from atherosclerosis probably by a greater mobilization of 
endothelial progenitor cells.77
In the young population, studies have shown that obesity 
is associated with increased arterial wall stiffness, as deter-
mined by carotid intima-media thickness.78,79 Diminished 
flow-mediated dilation has been observed in other patholo-
gies, such as Kawasaki disease and type 1 diabetes mellitus, 
but there is yet no direct relationship between obesity and 
altered flow-mediated dilation.80,81 Further studies are needed, 
but these are very promising markers for the early assessment 
of cardiovascular disease, even in young patients.
Transient elastography is a noninvasive method for detec-
tion of cirrhosis in patients with chronic liver disease by 
measuring the liver stiffness. It is a new method to   evaluate 
liver disease instead of biopsy, which is invasive and with 
potential life-threatening complications. It should also be 
pointed out that liver stiffness evaluation by using transient 
elastography measurements can be technically difficult in 
obese patients.82,83
Standard and new echocardiography techniques for the 
determination of coronary flow and early changes in systolic 
and diastolic left ventricle function are very important tools 
for assessing obese patients, even in the child population. 
Transthoracic Doppler echocardiography assessment of coro-
nary flow velocity is an established noninvasive and clinically 
useful method to provide physiological information on the 
coronary circulation in obese patients.84 New echocardiogra-
phy techniques, such as tissue Doppler imaging, strain, and 
strain rate, are useful tools for assessing cardiac dysfunction 
in adults and children. These techniques permit a quantitative 
assessment of both global and regional function and timing of 
myocardial events as well as the assessment of early changes 
in systolic and diastolic function.85–87
Strain and strain rate assess function in heart segments.88 
Strain is directly related to fiber shortening and strain rate 
is the speed of fiber shortening, which is a measure of 
  contractility.89 The longitudinal, radial, and circumferential 
function can be measured by tissue Doppler myocardial 
imaging and the B-mode imaging using the Speckle tracking 
technique.89 These methods are important to assessing sub-
clinical myocardial dysfunction in a wide variety of diseases 
and the application of strain analysis has been implemented 
in numerous experimental and clinical studies for the inves-
tigation of cardiac function.89
Early detection of cardiovascular abnormalities is very 
important because the control of this process seems to be 
more effective during the initial stages of the disease. The 
potential impact of obesity on biventricular function has not 
been fully established. Since traditional echocardiographic 
measurements of ventricular function, such as ejection fraction 
and mitral inflow for the evaluation of the diastolic function 
are load-dependent,90,91 the investigation of right and left 
ventricle subclinical dysfunction in obesity by sensitive newer 
echocardiographic techniques, such as tissue Doppler imaging, 
myocardial strain and strain rate looks like very promising.
Tissue Doppler imaging, strain, and strain rate have 
been introduced to better quantify segmental and global 
dysfunction, with studies showing clinically silent incipient 
dysfunction in obesity detected by strain and strain rate. 
Wong and colleagues used strain and strain rate to study 
myocardial function and found that overweight subjects 
have reduced systolic and diastolic function, even after 
adjustments for mean arterial pressure, age, gender, and left 
ventricular mass.92 In 2006, the same authors used the same 
techniques to demonstrate the existence of right ventricular 
dysfunction in obese patients.93 Gong and colleagues studied 
200 patients with metabolic syndrome using strain and 
strain rate to evaluate cardiac function in comparison to 
lean controls and demonstrated left ventricular systolic and 
diastolic dysfunction in the obese group. In the study, multiple 
regression analysis revealed that the waist-to-hip ratio was 
an independent predictor of systolic dysfunction and that the 
waist-to-hip ratio and high-density lipoproteins cholesterol 
were independent predictors of diastolic   dysfunction.94 Mehta 
and colleagues used tissue Doppler and found a decrease in 
diastolic function in obese children.95 In a prospective study 
involving healthy and obese individuals aged between 10 to 
18 years, Lorch and Sharkey found a decrease in systolic strain 
in the obese group in comparison to the lean group.96 More 
recently, Ingul and colleagues have reported an improvement 
in cardiac function, as evaluated by strain and strain rate, in 
obese adolescents after a training program.97
The left atrium is important in all phases of the cardiac 
cycle. During ventricular systole and isovolumic   relaxation, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Recent studies using tissue Doppler, strain, and strain rate to evaluate cardiac function in obese subjects
Author and  
year
Study population Cutoffs of BMI (kg/m2)  
or waist circumference (cm)
Results Commentary
Metha et al95 Obese children (n = 25) 
Control: 13.8 ± 1.9 years 
Obese: 14.4 ± 2.1 years
BMi . 25 (independent of age) Decrease in diastolic  
function
Healthy obese children with  
no comorbidities
wong et al92 Obese adults (n = 109)
Control: 46 ± 10 years
Overweight: 45 ± 11 years
Mild obesity: 42 ± 8 years
Severe obesity: 43 ± 10 years
Groups
1-BMi: 25–29.9 overweight
2-BMi: 30–34.9 mild obesity
3-BMi .35 severe obesity
Left ventricular systolic  
and diastolic dysfunction  
in patients with moderate  
to severe obesity
insulin levels were a  
significant predictor of  
systolic and diastolic heart  
dysfunction
Di Salvo et al105 Obese children (n = 150)
Control: 12 ± 3 years
Obese: 12 ± 3 years
Percentile .97th for sex and  
age (according to CDC)
Systolic dysfunction in  
both right and left  
ventricle
Healthy obese children with  
no comorbidities
wong et al93 Obese adults (n = 112)
Control: 43 ± 11 years
Overweight: 44 ± 10 years
Mild obesity: 41 ± 8 years
Severe obesity: 44 ± 13 years
BMi: 25–29.9 overweight
BMi: 30–34.9 mild obesity
BMi: .35 severe obesity
increase in BMi associated  
with increased severity of  
right ventricle dysfunction
BMi was associated with  
right ventricular dysfunction,   
regardless of sleep apnea
Lorch and  
Sharkey96
Obese children (n = 53)
Control: 13.9 ± 2.3
Obese: 13.8 ± 2.4
Percentile .95th for sex and  
age (CDC)*
Systolic and diastolic  
dysfunction of left  
ventricle
Retrospective study
Tumuklu et al106 Obese adults (n = 33)
Control: 43 ± 11
Moderate obesity: 42 ± 6
Severe obesity: 42 ± 8
BMi: 30–34.9 moderate obesity
BMi: .35 severe obesity
Systolic left ventricular  
dysfunction
Healthy obese subjects  
with no comorbidities
Di Salvo et al104 Obese children (n = 150)
Control: 12 ± 3 years
Obese: 12 ± 3 years
Percentile .97th for sex and  
age (according to CDC)
Reduced left and right  
atrial myocardial  
deformation
Healthy obese children  
with no comorbidities
Sürücü et al107 Obese adults (n = 25)
Control: 53 ± 6 years
Obese: 54 ± 8 years
BMi $ 27 Right and left ventricular  
systolic and diastolic  
dysfunction
Tissue Doppler technique  
and all subjects of the study  
with normal angiography
Gong et al94 Obese adults (n = 200)
Control: 49 ± 10 years
Obese: 50 ± 9 years
waist circumference $ 90 cm  
for men and $80 cm for  
women
Left ventricular systolic  
and diastolic dysfunction
Obese patients with  
comorbidities including  
hypertension, dyslipidemia  
and hyperglycemia
Gulel et al103 Obese adults (n = 37)
Control: 35 ± 5 years
Obese: 36 ± 11 years
BMi $ 30 kg/m2 No difference between  
groups considering left  
atrial function
No comorbidities
Orhan et al108 Obese adults (n = 29) 
Control: 47 ± 7 years 
Obese: 49 ± 8 years
BMi $ 30 kg/m2 Left and right ventricular  
systolic and diastolic  
dysfunction
No comorbidities
Abbreviations: BMi, body mass index; CDC, Centers for Disease Control and Prevention.
it serves as a reservoir that receives blood from the pulmo-
nary venous return and stores energy in the form of pres-
sure. During the early phase of ventricular diastole, the left 
atrium operates as a conduit for transferring blood into the 
left ventricle following the opening of the mitral valve due 
to a pressure gradient and through which blood flows pas-
sively from the pulmonary veins into the left ventricle; the 
contractile function of the left atrium, during the late phase 
of diastole, increases the left ventricular stroke volume by 
nearly 20%.71
Left atrial size is an expression of chronic left ventricular 
filling pressures. Early studies had demonstrated the value of 
left ventricular diameter in predicting prognosis of cardiac 
diseases and in the development of atrial fibrillation. More 
recently, left atrial volume has been shown to be an important 
and more accurate measurement of left atrial size and this 
measurement, indexed to body surface area, has been used 
to predict prognosis in several heart diseases.71,98,99 Although 
left atrial volume seems to correlate with diastolic filling 
pressures, accurate and direct measurements of the left atrial 
function have not been established.
Enlargement of the atria is associated with obesity and 
has been also linked with an increased risk of mortality.100 
Using standard echocardiography techniques, Hirschler and Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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colleagues concluded that left atrial enlargement is related 
to abdominal obesity and hypertension in children.101 Kosar 
and colleagues found that obese patients without cardiovas-
cular disease exhibit enlargement of left atrium in standard 
echocardiography.102
Strain and strain rate methods have emerged as promising 
methods to evaluate atrial function, but with controversial 
results. Gulel and colleagues compared left atrial func-
tion using color tissue Doppler imaging in adults with a 
BMI $ 30 kg/m2 versus those with a BMI , 30 kg/m2 and 
found no differences in systolic or diastolic atrial function 
between groups.103 On the other hand, Di Salvo and col-
leagues studied nonhypertensive children using strain and 
strain rate and found reduced left and right atrial function in 
the obese group.104 Further studies should be carried out to 
clarify these controversial results.
In summary, obesity, even without comorbidities, is 
generally associated with cardiac events. Overt systolic and 
diastolic dysfunction has been described in obesity. New 
findings, indicating the occurrence of pre-clinical systolic 
and diastolic dysfunction, even in young obese patients, 
suggest that obese patients should be carefully monitored 
in order to detect incipient dysfunction. Efforts should be 
made, not only to make obese patients lose weight and control 
other cardiovascular risk factors, but also to detect incipient 
atrial and ventricular dysfunction. If these patients should be 
treated before the development of overt ventricular dysfunc-
tion, remains to be established. Table 1 summarizes the most 
recent studies using tissue Doppler imaging, strain and strain 
rate to evaluate cardiac function in obese subjects.
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